Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

Giuseppe Lamberti, Antongiulio Faggiano, Nicole Brighi, Salvatore Tafuto, Toni Ibrahim, Maria Pia Brizzi, Sara Pusceddu, Manuela Albertelli, Sara Massironi, Francesco Panzuto, Giuseppe Badalamenti, Ferdinando Riccardi, Giovanni Butturini, Fabio Gelsomino, Chiara De Divitiis, Roberta Modica, Alberto Bongiovanni, Anna La Salvia, Martina Torchio, Annamaria ColaoDiego Ferone, Davide Campana

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. METHODS: A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or shortened interval between administrations [dose density]). Main endpoints were progression-free survival (PFS) and safety. RESULTS: Of 198 patients, 140 matched inclusion criteria and were included in the analysis. Overall, median PFS was 31 months. Use of HD-SSA as second-line treatment was associated with reduced risk for progression or death compared with third- or further-line treatment (HR: 2.12; P = 0.004). There was no difference in PFS between HD-SSA by increased dose density (N = 133; 95%) or intensity (N = 7; 5%). Partial response according to RECIST criteria was observed in 12 patients (8.6%), and stable disease was achieved in 106 (75.7%) patients. Adverse events occurred in 21 patients (15.0%), 2 of whom had grade 3 biliary stone disease. No patients discontinued HD-SSA treatment due to adverse events. CONCLUSIONS: HD-SSA is an active and safe treatment option in patients with progressive well-differentiated GEP-NET. The high rate of objective responses observed deserves prospective validation in ad hoc clinical trials.

Original languageEnglish
JournalThe Journal of clinical endocrinology and metabolism
Volume105
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

    Fingerprint

Keywords

  • high dose
  • lanreotide
  • NET
  • nonconventional doses
  • octreotide
  • somatostatin analogs

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Lamberti, G., Faggiano, A., Brighi, N., Tafuto, S., Ibrahim, T., Brizzi, M. P., Pusceddu, S., Albertelli, M., Massironi, S., Panzuto, F., Badalamenti, G., Riccardi, F., Butturini, G., Gelsomino, F., De Divitiis, C., Modica, R., Bongiovanni, A., La Salvia, A., Torchio, M., ... Campana, D. (2020). Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. The Journal of clinical endocrinology and metabolism, 105(1). https://doi.org/10.1210/clinem/dgz035